You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 13 No. 6, December 1965 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Biochemical Correlates of Behavior in Schizophrenic Patients

Schizophrenic Patients Receiving Tryptophan and Methionine or Methionine Together With a Monoamine Oxidase Inhibitor

H. H. BERLET, MD; K. MATSUMOTO, MD; G. R. PSCHEIDT, PhD; J. SPAIDE, MS; C. BULL, MD; H. E. HIMWICH, MD

Arch Gen Psychiatry. 1965;13(6):521-531.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THE FIRST part of this longitudinal study,3,6 a reduced intake of methionine and tryptophan failed to affect schizophrenic behavior conclusively. During this period of seven months of continuously controlled tryptophan intake we found that increases of urinary indoles occurred independently of tryptophan intake when schizophrenic symptoms in some of the patients grew worse spontaneously. The excretions of catecholamines34 and urinary steroid hormones28 were also elevated with accompanying motor hyperactivity, increased tension and anxiety.

The objective of the second part of this investigation was to study the behavioral responses to increases of methionine and tryptophan as well as that of methionine given together with a monoamine oxidase inhibitor (MAOI). Both improvement and worsening of behavior have been reported for normal, schizophrenic, and depressed subjects.9,14,27,32 It appeared, therefore, of interest to study urinary excretion patterns in relation to amino acid intake and accompanying . . . [Full Text PDF of this Article]


Author Affiliations

GALESBURG, ILL

From the Thudichum Psychiatric Research Laboratory, Galesburg State Research Hospital. Department of Neuropsychiatry, Osaka University Medical School, Osahi-Machi, Aben-Ku, Osaka, Japan (Dr. Matsumoto) and Butler Hospital, Providence, RI (Dr. Bull).


Footnotes

Submitted for publication March 18, 1965.

Reprint requests to State of Illinois Department of Mental Health Galesburg State Research Hospital, Galesburg, Ill 61404 (Dr. Himwich).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1965 American Medical Association. All Rights Reserved.